BRPI1006829A2 - tratamento de um câncer empregando uma combinação de bendamustina e um anticorpo anti-cd20 - Google Patents
tratamento de um câncer empregando uma combinação de bendamustina e um anticorpo anti-cd20Info
- Publication number
- BRPI1006829A2 BRPI1006829A2 BRPI1006829A BRPI1006829A BRPI1006829A2 BR PI1006829 A2 BRPI1006829 A2 BR PI1006829A2 BR PI1006829 A BRPI1006829 A BR PI1006829A BR PI1006829 A BRPI1006829 A BR PI1006829A BR PI1006829 A2 BRPI1006829 A2 BR PI1006829A2
- Authority
- BR
- Brazil
- Prior art keywords
- bendamustine
- antibody
- combination
- cancer treatment
- treatment employing
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title 1
- 229960002707 bendamustine Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14521009P | 2009-01-16 | 2009-01-16 | |
| PCT/US2010/021123 WO2010083365A1 (en) | 2009-01-16 | 2010-01-15 | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006829A2 true BRPI1006829A2 (pt) | 2016-10-25 |
Family
ID=42340093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006829A BRPI1006829A2 (pt) | 2009-01-16 | 2010-01-15 | tratamento de um câncer empregando uma combinação de bendamustina e um anticorpo anti-cd20 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110274697A1 (pt) |
| EP (1) | EP2405937A4 (pt) |
| JP (1) | JP2012515217A (pt) |
| KR (1) | KR20110111303A (pt) |
| CN (1) | CN102355907A (pt) |
| AU (1) | AU2010204666A1 (pt) |
| BR (1) | BRPI1006829A2 (pt) |
| CA (1) | CA2749151A1 (pt) |
| EA (1) | EA201170940A1 (pt) |
| IL (1) | IL213794A0 (pt) |
| MX (1) | MX2011007589A (pt) |
| SG (1) | SG172792A1 (pt) |
| WO (1) | WO2010083365A1 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| EP2744515B1 (en) * | 2011-08-16 | 2022-02-09 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a nitrogen mustard |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| FR2980110A1 (fr) * | 2011-09-20 | 2013-03-22 | Lfb Biotechnologies | Combinaison d'anticorps anti-cd20 et de bendamustine |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EP3484466A1 (en) * | 2016-07-13 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| WO2019228406A1 (en) * | 2018-05-29 | 2019-12-05 | Wuxi Biologics (Shanghai) Co., Ltd. | A novel anti-cd3/anti-cd20 bispecific antibody |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| WO2020081148A1 (en) | 2018-10-16 | 2020-04-23 | US Nano Food & Drug INC | Intratumor injection formulation |
| BR112022014701A2 (pt) | 2020-04-13 | 2022-10-25 | US Nano Food & Drug INC | Formulação de injeção intratumoral quimioterápica básica |
| WO2022022464A1 (zh) | 2020-07-27 | 2022-02-03 | 正大天晴药业集团股份有限公司 | 新型双特异性抗cd3/cd20多肽复合物配制剂 |
| GB202218493D0 (en) * | 2022-12-08 | 2023-01-25 | Oncopeptides Ab | Novel therapeutic combinations |
| WO2024179545A1 (zh) * | 2023-03-01 | 2024-09-06 | 上海津曼特生物科技有限公司 | 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途 |
| WO2024263798A1 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating prostate cancer |
| WO2024263804A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating kidney cancer |
| WO2024263801A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating ovarian cancer |
| WO2024263813A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating colorectal cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL216630B1 (pl) * | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| EP2236172A1 (en) * | 2003-11-04 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| US8802089B2 (en) * | 2008-01-03 | 2014-08-12 | Genmab A/S | Monoclonal antibodies against CD32B |
-
2010
- 2010-01-15 US US13/144,335 patent/US20110274697A1/en not_active Abandoned
- 2010-01-15 BR BRPI1006829A patent/BRPI1006829A2/pt not_active IP Right Cessation
- 2010-01-15 SG SG2011047107A patent/SG172792A1/en unknown
- 2010-01-15 AU AU2010204666A patent/AU2010204666A1/en not_active Abandoned
- 2010-01-15 EP EP10732123A patent/EP2405937A4/en not_active Withdrawn
- 2010-01-15 KR KR1020117018826A patent/KR20110111303A/ko not_active Withdrawn
- 2010-01-15 JP JP2011546347A patent/JP2012515217A/ja active Pending
- 2010-01-15 WO PCT/US2010/021123 patent/WO2010083365A1/en not_active Ceased
- 2010-01-15 CA CA2749151A patent/CA2749151A1/en not_active Abandoned
- 2010-01-15 EA EA201170940A patent/EA201170940A1/ru unknown
- 2010-01-15 CN CN2010800123232A patent/CN102355907A/zh active Pending
- 2010-01-15 MX MX2011007589A patent/MX2011007589A/es not_active Application Discontinuation
-
2011
- 2011-06-27 IL IL213794A patent/IL213794A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2405937A4 (en) | 2012-06-20 |
| JP2012515217A (ja) | 2012-07-05 |
| KR20110111303A (ko) | 2011-10-10 |
| WO2010083365A1 (en) | 2010-07-22 |
| US20110274697A1 (en) | 2011-11-10 |
| CN102355907A (zh) | 2012-02-15 |
| EA201170940A1 (ru) | 2012-02-28 |
| AU2010204666A1 (en) | 2011-07-21 |
| EP2405937A1 (en) | 2012-01-18 |
| CA2749151A1 (en) | 2010-07-22 |
| MX2011007589A (es) | 2011-08-17 |
| SG172792A1 (en) | 2011-08-29 |
| IL213794A0 (en) | 2011-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006829A2 (pt) | tratamento de um câncer empregando uma combinação de bendamustina e um anticorpo anti-cd20 | |
| HUS1700041I1 (hu) | Kombinált afukozilált anti-CD20 antitest terápia bendamusztinnal | |
| CY2017019I2 (el) | Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| EP2498853A4 (en) | PATIENT INTERFACE AND ASPECTS OF IT | |
| EP2265283A4 (en) | Auristatin-DRUG-LINKER CONJUGATES | |
| BRPI1010895A2 (pt) | conjunto de lâminas germicidas e luminárias | |
| BR112013014316A2 (pt) | tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1 | |
| BR112012001637A2 (pt) | dispositivo médico implantável | |
| HRP20160579T1 (hr) | Spoj indola i njegova farmaceutska upotreba | |
| EP2448492A4 (en) | IMAGE-GUIDED RADIOTHERAPY | |
| EP2422846A4 (en) | CORPUSCULAR RADIATION THERAPY APPARATUS | |
| PT2582683T (pt) | Tratamento da gota e de hiperuricemia | |
| EP2442821A4 (en) | SAFE ADMINISTRATION OF DESMOPRESSIN | |
| PL2435825T3 (pl) | Sposoby leczenia chorób | |
| BRPI0922804A2 (pt) | formas de dosagem sólidas de bendamustina | |
| BR112012007861A2 (pt) | dispositivos médicos e suas bombas | |
| BR112012010242A2 (pt) | derivados de heteroarilpiperidina e heteroarilpiperazina | |
| UY33111A (es) | Jeringas | |
| BRPI1011319A2 (pt) | derivados de triazina benzil-substituídos e suas aplicações terapêuticas | |
| BR112013002544A2 (pt) | seção de armario e armario | |
| BRPI1014688A2 (pt) | aplicações terapêuticas de derivados de quinazolinadiona | |
| SMT201700056B (it) | Fosfaplatine e relativo utilizzo per il trattamento di cancro | |
| BR112013002441A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer | |
| EP2614300A4 (en) | RADIATION SOURCE ASSEMBLY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |